Cronos Group (CRON) versus Its Rivals Head-To-Head Analysis

Cronos Group (NASDAQ:CRON) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Cronos Group to related companies based on the strength of its valuation, profitability, analyst recommendations, dividends, risk, institutional ownership and earnings.

Risk and Volatility

Cronos Group has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Cronos Group’s peers have a beta of -4.29, suggesting that their average stock price is 529% less volatile than the S&P 500.

Institutional & Insider Ownership

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cronos Group and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cronos Group	$146.59 million	-$9.45 million	16.50
Cronos Group Competitors	$3.54 billion	$3.17 billion	546.63

Cronos Group’s peers have higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Cronos Group and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cronos Group	39.08%	4.85%	4.62%
Cronos Group Competitors	-2,380.91%	-221.72%	-15.99%

Analyst Ratings

This is a summary of current ratings and target prices for Cronos Group and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0	1	3	1	3.00
Cronos Group Competitors	7765	13847	25696	1031	2.41

Cronos Group currently has a consensus price target of $2.30, indicating a potential downside of 30.30%. As a group, “Pharmaceuticals” companies have a potential upside of 24.00%. Given Cronos Group’s peers higher possible upside, analysts clearly believe Cronos Group has less favorable growth aspects than its peers.

Summary

Cronos Group beats its peers on 7 of the 13 factors compared.

Cronos Group Company Profile

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.